Obstructing Spontaneous Major Shunt Vessels is Mandatory to Keep Adequate Portal Inflow in Living-Donor Liver Transplantation

Toru Ikegami, Ken Shirabe, Hidekazu Nakagawara, Tomoharu Yoshizumi, Takeo Toshima, Yuji Soejima, Hideaki Uchiyama, Yo-Ichi Yamashita, Norifumi Harimoto, and Yoshihiko Maehara

Background. It has not been addressed whether the major spontaneous portosystemic shunt vessels should be ligated in living-donor liver transplantation (LDLT).
Methods. We performed a retrospective analysis of 324 cases of adult-to-adult LDLT.
Results. Factors associated with the presence of major (>10 mm) shunt vessels (n=130) included portal vein (PV) thrombosis (27.7%), lower PV pressure at laparotomy, Child-Pugh class C, and transplantation of right-side grafts. The types of major portosystemic shunt vessels included splenorenal shunts (46.2%), gastroesophageal shunts (26.9%), mesocaval shunts (13.8%), and others (13.1%). Ligation of the major shunt vessels increased PV pressure (mean [SD], from 16.8 [3.9] mm Hg to 18.6 [4.3] mm Hg; $P<0.001$) and PV flow (mean [SD], from 1.35 [0.67] L/min to 1.67 [0.67] L/min; $P<0.001$) into the grafts. Post-LDLT computed tomography showed patent major shunts in 14 patients. Nine of such patients (64.3%) with unligated major shunt vessels (undetected shunt vessels, n=5; incomplete ligation, n=2; and the shunt was newly created or left open to maintain high PV pressure after reperfusion, n=3) required secondary interventions. Two of these patients died because of graft dysfunction. PV flow was significantly lower in the nine patients who underwent secondary ligation of the major shunt vessels compared with patients with successful primary ligation (mean [SD], 0.96 [0.34] L/min vs. 1.65 [0.63] L/min; $P=0.001$).
Conclusions. It is an appropriate option to obstruct the major portosystemic shunt vessels to ensure adequate graft inflow in LDLT.

Keywords: Shunt vessels, Portal vein, Living-donor liver transplantation, Splenectomy.

(*Transplantation* 2013;95: 1270–1277)

Portal hypertension is a common outcome of end-stage liver disease, and it causes gastrointestinal bleeding, hypersplenism, intractable ascites, and hepatic encephalopathy (*1*). For treating such portal hypertension, transjugular intrahepatic portosystemic shunt has been commonly applied mainly in Western countries, resulting in uncommon development of tremendous or major shunt vessels (*2, 3*). In Eastern countries including Japan, however, transjugular shunting approach is less commonly used and replaced by other types of endoscopic or interventional treatment (*4, 5*), and therefore, patients who are referred for liver transplantation frequently have major portosystemic shunt vessels.

Liver transplantation is the ultimate treatment of portal hypertension, and it is known that splenomegaly and major spontaneous portosystemic shunts recover after whole-liver transplantation (*6–9*). On the other hand, after living-donor liver transplantation (LDLT), transient or persistent portal hypertension with increased portal vein (PV) resistance could occur even after surgery because of significant graft regeneration and small-for-size graft dysfunction (*10–12*). Thus, in LDLT recipients with major portosystemic shunt vessels, increased PV pressure might cause portal steal phenomenon, resulting in insufficient portal inflow and graft dysfunction (*13–15*).

In this study, we retrospectively analyzed 324 adult LDLT cases to determine the clinical characteristics of patients with major spontaneous portosystemic shunt vessels and, ultimately, to assess whether such major shunts need to be obstructed in LDLT.

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Health, Labor, and Welfare of Japan.
The authors declare no conflicts of interest.
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Address correspondence to: Toru Ikegami, M.D., Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
E-mail: tikesurg@ysurg2.med.kyushu-u.ac.jp
T.I. participated in making the concept and design of the study and in drafting the manuscript. K.S. participated in the critical revision of the manuscript. H.N., T.T., H.U., Y.Y., and N.H. participated in collecting the data. T.Y. participated in making the study design and in the critical revision of the manuscript. Y.S. participated in making the concept and design of the study. Y.M. participated in the final approval of the manuscript.
Received 26 November 2012. Revision requested 20 December 2012.
Accepted 18 January 2013.

ISSN: 0041-1337/13/9510-1270
DOI: 10.1097/TP.0b013e318288cadc

RESULTS

Characteristics of the Recipients, Donors, and Grafts

The mean (SD) age of the recipients was 52.4 (11.3) years. Indications for LDLT included cholestatic cirrhosis (n=85, 26.2%), postnecrotic viral or nonviral cirrhosis (n=229, 70.7%), and others (n=10, 3.1%). Approximately half of the patients were hepatitis C virus positive (n=154, 47.5%). Almost two-third of the patients were classified as Child-Pugh class C (n=206, 63.6%). The mean (SD) model for end-stage liver disease score was 15.8 (6.1). Major shunt vessels were present in 130 recipients (40.1%). The mean (SD) age of the donors was 36.5 (11.3) years. Graft types included left-lobe (n=197, 60.8%), right-lobe (n=120, 37.0%), and posterior segment (n=7, 2.2%) grafts. Twelve donors (4.3%) provided blood type–incompatible grafts. The mean (SD) graft volume (GV) and GV/standard liver volume (SLV) were 478 (105) g and 41.5 (8.5), respectively. Splenectomy was performed in 165 recipients (50.9%). The mean (SD) operation time was 807 (185) min, and the mean (SD) blood loss was 7.7 (16.1) L.

TABLE 1. Patient demographics

Variables	Presence of Major Shunt Vessels		P
	No (n=194)	Yes (n=130)	
Recipient age, mean (SD), y	51.9 (11.6)	53.0 (10.8)	0.409
Recipient gender, male, n (%)	104 (53.6)	56 (43.1)	0.063
Child-Pugh class C, n (%)	113 (58.2)	93 (71.5)	0.015
MELD score, mean (SD)	15.3 (6.6)	16.4 (5.3)	0.109
Hospitalized status, n (%)	68 (35.1)	44 (42.3)	0.187
PV thrombosis before LDLT, n (%)	8 (4.1)	36 (27.7)	<0.001
Hepatocellular carcinoma, n (%)	99 (51.9)	63 (48.5)	0.650
Donor age, mean (SD), y	36.9 (11.2)	35.9 (11.5)	0.407
Donor gender, male, n (%)	130 (67.0)	76 (58.5)	0.117
Blood type–incompatible donor, n (%)	7 (3.6)	7 (5.4)	0.447
Left-lobe graft, n (%)	131 (67.5)	66 (50.7)	0.002
GV, mean (SD), g	472 (106)	486 (104)	0.282
GV/SLV ratio, mean (SD), %	41.1 (8.5)	41.9 (8.4)	0.391
PV pressure at laparotomy, mean (SD), mm Hg	25.0 (5.8)	23.8 (5.4)	0.048
PV pressure at the closure, mean (SD), mm Hg	17.1 (4.2)	17.1 (4.3)	0.856
PV flow, mean (SD), L/min/graft	1.68 (0.40)	1.68 (0.65)	0.995
HA flow, mean (SD), mL/min	110 (70)	103 (68)	0.449
Operation time, mean (SD), min	802 (179)	813 (192)	0.585
Operative blood loss, mean (SD), L	8.4 (19.1)	6.6 (10.1)	0.305
Acute cellular rejection, n (%)	30 (15.4)	16 (12.3)	0.425
PV thrombosis, n (%)	3 (1.5)	5 (3.8)	0.190
Bacteremia, n (%)	21 (10.8)	18 (13.9)	0.398
Primary graft dysfunction, n (%)	21 (10.8)	22 (16.9)	0.112

GV, graft volume; HA, hepatic artery; LDLT, living-donor liver transplantation; MELD, model for end-stage liver disease; PV, portal vein; SLV, standard liver volume.

Factors associated with the presence of major spontaneous portosystemic shunt vessels were evaluated (Table 1). Patients with major shunt vessels more frequently had PV thrombosis before transplantation compared with patients without major shunt vessels (27.7% vs. 4.1%, $P<0.001$) before transplantation. Patients with major portosystemic shunt vessels also had lower PV pressure at laparotomy (mean [SD], 23.8 [5.4] mm Hg vs. 25.0 [5.8] mm Hg; $P=0.048$), were more often classified as Child-Pugh class C (71.5% vs. 58.2%, $P=0.015$) and were more likely to receive right-side grafts, including right-lobe and posterior segment grafts (49.3% vs. 32.5%, $P=0.002$). There were no other differences in preoperative and operative factors between patients with and without major portosystemic shunt vessels. Although the incidence of hepatic artery thrombosis was higher in patients with major portosystemic shunts before LDLT (2.3% vs. 0.0%, $P=0.033$), there were no differences in other postoperative factors.

Types of Shunt Vessels

The types of major portosystemic shunt vessels (n=130; Table 2) included splenorenal shunts (n=60, 46.2%), gastroesophageal shunts (n=35, 26.9%), mesocaval shunts (n=18, 13.8%), paraumbilical shunts (n=16, 12.3%), and cavernous transformation in the hepatoduodenal ligament (n=1, 0.8%). A total of 36 patients (27.7%) had PV thrombosis, including an atrophic PV (n=3), or complete (n=14), partial (n=15), or luminal PV thrombosis (n=4). In four patients, a splenorenal shunt was used for renoportal anastomosis to establish PV inflow (Table 2).

Ligation of the Shunt Vessels and PV Pressure

Ligation of major portosystemic shunt vessels significantly increased mean (SD) PV pressure from 16.8 (3.9) mm Hg to 18.6 (4.3) mm Hg ($P<0.001$) and PV flow from 1.35 (0.67) mm Hg to 1.67 (0.67) mm Hg ($P<0.001$). Concomitant splenectomy decreased mean (SD) PV pressure by 3.9 (0.8) mm Hg.

PV Reconstruction in Patients with PV Thrombosis

For patients with PV thrombosis, graft PV inflow was established by renoportal anastomosis (n=4), interposing an internal jugular (IJ) vein graft (n=3) between the superior mesenteric vein and graft PV, thrombectomy (n=25), or direct anastomosis (n=4). The other 94 patients (72.3%) did not have PV thrombosis before LDLT.

For patients with a splenorenal shunt and severe PV thrombosis, including an atrophic PV (n=4), renoportal anastomosis was performed to establish PV inflow. Right-lobe grafts were transplanted for appropriate vascular alignment and to accommodate the vast inflow from the mesenteric, splenic, and left renal veins (Table 2).

For patients with a mesocaval shunt and severe PV thrombosis, including patients with an atrophic PV (n=2), we used IJ jump grafts. In one patient with an atrophic PV, the atrophied PV was dissected down to the junction of the mesenteric and splenic veins, and the IJ vein graft was directly anastomosed onto the exposed junction. In the other

TABLE 2. The types of the shunts and portal vein thrombosis

Shunts	PV Thrombosis	Procedures for PV Thrombosis and Major Shunts
Splenorenal shunt (n=60)	Atrophic PV (n=2)	Renoportal anastomosis using IJ vein (n=2)
	Complete (n=7)	Renoportal anastomosis using IJ vein (n=2)
		Thrombectomy+shunt ligation (n=5)
	Partial (n=6)	Thrombectomy+shunt ligation (n=6)
	Luminal (n=1)	Direct anastomosis+shunt ligation (n=1)
	No PV thrombosis (n=44)	Shunt ligation (n=36)
		No (n=7) or incomplete (n=1) shunt ligation, followed by secondary ligation (n=4)
Gastroesophageal shunt (n=35)	Complete (n=5)	Thrombectomy+shunt ligation (n=5)
	Partial (n=3)	Thrombectomy+shunt ligation (n=3)
	Luminal (n=2)	Direct anastomosis+shunt ligation (n=2)
	No PV thrombosis (n=25)	Shunt ligation (n=21)
		No shunt ligation (n=4), followed by secondary ligation (n=3)
Mesocaval shunt (n=18)	Atrophic PV (n=1)	Interposition using IJ vein+shunt ligation (n=1)
	Complete (n=1)	Interposition using IJ vein (behind pancreas)+shunt ligation (n=1)
	Partial (n=3)	Thrombectomy+shunt ligation (n=2)
		Thrombectomy+incomplete shunt ligation, followed by secondary ligation (n=1)
	No PV thrombosis (n=13)	Shunt ligation (n=13)
Paraumbilical shunt (n=16)	Partial (n=3)	Thrombectomy+shunt ligation (n=3)
	Luminal (n=1)	Direct anastomosis+shunt ligation (n=1)
	No PV thrombosis (n=12)	Shunt ligation (n=12)
Cavernous transformation (n=1)	Complete (n=1)	Interposition using IJ vein (behind pancreas)

IJ, internal jugular, PV, portal vein.

patient with complete PV thrombosis and a very fragile PV wall caused by cholangitis, the IJ vein graft was anastomosed to the mesenteric vein in an end-to-side fashion, tunneled behind the pancreas neck and connected to the graft's PV.

For the patient with cavernous transformation, the shunt vessels in the hepatoduodenal ligament were divided under mechanical portocaval shunting from the inferior mesenteric vein into the axillar vein. The IJ vein graft was connected to the mesenteric vein in an end-to-end fashion, tunneled behind the pancreas neck, and was connected to the graft's PV.

Untied or Newly Created Shunt Vessels

Ligation of the major shunt vessels was not performed in 13/130 patients (10.0%), and a new hemiportocaval shunt was created in another patient. Therefore, 14 patients had major shunt vessels after LDLT. The reasons for having patent major shunt vessels after LDLT included undetected vessels (n=9), incomplete ligation (n=2), or the shunt was newly created or left open to maintain high PV pressure after reperfusion (n=3). Nine patients (62.3%) required secondary interventions (Table 3, Fig. 1). Among them, six cases had small-for-size graft syndrome like primary graft dysfunction, and one had cholangitis caused by biliary anastomotic stricture after LDLT.

PV flow was significantly lower in the patients who underwent secondary ligation of the major shunt vessels (n=9) than in the patients without the secondary procedure (n=121) (mean [SD], 0.96 [0.25] L/min vs. 1.62 [0.62] L/min; P=0.007). By contrast, PV pressure at the end of surgery was not significantly different between these two groups of patients (18.6 [3.9] mm Hg vs. 17.1 [4.4] mm Hg, P=0.604).

Graft Survival

The presence of major shunt vessels or PV thrombosis did not significantly affect graft survival. The 1- and 5-year cumulative graft survival rates were 90.7% and 83.0%, respectively, in patients without major shunts vessels versus 86.1% and 77.2%, respectively, in patients with major shunt vessels (P=0.195). The 1- and 5-year cumulative graft survival rate was 97.8% and 82.3%, respectively, in patients without PV thrombosis versus 84.0% and 70.6%, respectively, in patients with PV thrombosis (P=0.119).

DISCUSSION

In deceased-donor whole-liver transplantation, it is generally considered that special interventions are not necessary for spontaneous portosystemic shunts or hypersplenism. In Western countries in particular, nonsurgical transjugular intrahepatic portosystemic shunts have supplanted surgical shunts for pretransplantation management of portal hypertension and achieved sufficient portal decompression (*4–6*). In LDLT, however, there is no consensus on whether spontaneous portosystemic shunts should be obstructed, although some reports have described secondary interventions for patent portosystemic shunts with portal steal phenomenon (*13–15*). Moreover, the beneficial effects of surgically created portocaval shunts for small-for-size grafts have been widely advocated in recent years (*16, 17*). Nevertheless, there is no consensus on whether the shunt should be closed, kept, or

TABLE 3. The patients who underwent secondary intervention for obstructing shunt vessels after LDLT

Case No.	Age, Sex	Graft	GV/SLV ratio (%)	Shunt Type	Reason for Left Open	PV Pressure (mm Hg)	PV Flow (mL/min)
1	40, M	Left	28.9	Splenorenal	Unrecognized shunts	N/A	1150
2	47, F	Left	40.5	Splenorenal	Unrecognized shunts	N/A	770
3	53, F	Left	38.2	Splenorenal	Unrecognized shunts	22	1500
4	40, M	Left	44.7	Mesocaval	Incomplete shunt ligation	15	980
5	53, M	Right	42.9	Gastroesophageal	Unrecognized shunts	12	900
6	51, F	Post	38.6	Splenorenal	Unrecognized shunts	15	790
7	47, F	Left	23.7	Hemiportocaval	Created for high PV pressure	21	270
8	47, F	Left	35.6	Gastroesophageal	Left open for high PV pressure	21	1340
9	62, F	Left	35.4	Gastroesophageal	Left open for high PV pressure	24	990

Case No.	Intervention After LDLT	Indication	Method	Outcome
1	1st day	Decreased PV flow Graft dysfunction	Relaparotomy	Treated
2	133th day	Risky gastric varices	BRTO	Treated
3	82th day	Risky gastric varices	BRTO	Treated
4	1st day	Decreased PV flow Graft dysfunction	Relaparotomy	Treated
5	8th day	Decreased PV flow Graft dysfunction	Relaparotomy	Treated
6	22th day	Decreased PV flow Graft dysfunction	BRTO	Dead
7	4th day	Decreased PV flow Graft dysfunction	Relaparotomy	Treated
8	57th day	Encephalopathy	Relaparotomy	Treated
9	8th day	Decreased PV flow Graft dysfunction	Relaparotomy	Dead

BRTO, balloon-occluded retrograde transvenous obliteration; GV, graft volume; LDLT, living-donor liver transplantation; N/A, not applicable; PV, portal vein; SLV, standard liver volume.



FIGURE 1. The cases of patient major shunt vessels requiring secondary intervention: Case 4 (A–C) and Case 8 (C, D). Mesenteric arterioportogram (A) and computed tomographic scan (B) showed portal steal caused by patent major mesocaval shunt, followed by surgical ligation (C). Multidetector computed tomographic image of patent gastroesophageal shunt after LDLT (D), followed by surgical ligation (E).

created, nor have the indications, such as PV pressure of PV flow, for shunt management been assessed.

In our institute, the management of portal hemodynamic status has changed considerably with our accumulating experience. Before 2000, we did not perform shunt ligation or splenectomy. However, since 2000, when we experienced a case of graft dysfunction caused by portal steal through a splenorenal shunt, we have ligated the major shunts, whenever possible. In 2001, we started to apply splenic artery ligation for patients with small-for-size graft dysfunction and increased PV pressure and then adopted splenectomy in 2005 (*18, 19*). Following several reports published in the mid-2000s showing the beneficial effects of creating portocaval shunt for reducing PV pressure and PV flow, we created portocaval shunts or kept the major shunts in three patients to reduce high PV pressure after reperfusion, albeit with poor outcomes (*20*). These three cases showed more graft portal resistance caused by dynamic graft regeneration and reduced PV flow, which was diverted into the portosystemic shunts (*10, 12, 15*). Hemiportocaval shunting is considered to be neither stable nor safe because the flow rate into the graft and shunt cannot be controlled in a dynamically regenerating liver graft (*20*). In fact, a

similar discussion was previously reported in the context of portal steal phenomenon in auxiliary partial liver transplantation, and a consensus was obtained for ligating the PV of the native liver to provide constant PV flow into a regenerating auxiliary graft (*21, 22*). Thus, our current strategy for the management of PV hemodynamic status in LDLT (i.e., shunt ligation to prevent portal stealing and splenectomy for PV decompression) simplifies and normalizes PV hemodynamic management.

We have implemented several technical refinements to approach and treat portosystemic shunts, including en bloc stapling division of gastroesophageal varices and a direct approach for splenorenal shunts. Gastroesophageal shunts are often coiled or tortuous, engorged with a thin wall, sometimes multiple in number, and are usually buried in the retroperitoneum on the diaphragmatic crus (*15, 23*). Because manual isolation and ligation of such vessels is technically very difficult, our technique to divide these vessels, including the left gastric artery en bloc, is safe and simultaneously decreases portal inflow through the left gastric artery (*23*).

The approach for splenorenal shunts is also technically demanding. Lee et al. (*24*) recently reported a novel technique involving ligation of the left renal vein to prevent portal stealing through the splenorenal shunt. However, they also reported that ligation of the left renal vein decreased kidney size in 75% of the recipients. Therefore, they concluded that the procedure should be limited to a life-saving procedure (*24*). We expose the left renal vein and follow it to identify splenorenal shunts originating from the left adrenal vein. We think that normal anatomic structures, including the left renal vein and left adrenal vein, have appropriate venous shapes and thicknesses, unlike abnormal venous shunts, and following such veins can be performed safely.

The surgical technique to establish PV inflow is another issue that needs to be addressed for patients with portosystemic shunts. We use corkscrew technique for PVs extending into the splenomesenteric junction. For atrophic PV, we consider patch plasty, renoportal anastomosis, or placing an interposition graft under the pancreas neck between the superior mesenteric vein and the graft's PV. Renoportal anastomosis may be applied for patients with a splenorenal shunt (*25*). To place an interposition graft, it is not always possible to procure a long venous segment to join the superior mesenteric vein with the graft PV over the pancreas, especially in Japan, where deceased-donor venous grafts are rare (*26*). Instead, we use the IJ vein, which is tunneled under the pancreas neck. Nevertheless, it is necessary that sufficient PV inflow is maintained after obstructing the major shunts. Indeed, we recently reported that a postreperfusion PV flow of less than 1 L/min is a significant risk factor for relaparotomy for inadequate PV flow (*27*).

Pretransplantation evaluation of PV hemodynamic status is useful to identify the major shunt to be ligated. To achieve this, we have used multidetector-row computed tomography (MDCT) to provide three-dimensional images of PV circulation since 2007. Numerous reports have confirmed the usefulness of MDCT for visualizing the arterial, portal, and venous vasculature systems (*15*). Although six patients before 2006 had undetected or incompletely ligated shunts requiring secondary intervention, there have been no further cases after the introduction of three-dimensional MDCT. If PV flow after reperfusion was less than 1 L/min, cineportograms could be performed, as suggested by Moon et al. (*15*).

PV hemodynamics is influenced by various factors including graft inflows and outflows, graft compliance, and central venous pressure. Partial LDLT grafts are more susceptible to these changes than the whole-liver graft (*28*). In the nine cases undergoing secondary intervention for PV stealing phenomenon, six had primary graft dysfunction (*29*), and one had cholangitis caused by biliary anastomotic stricture after LDLT. Moreover, graft regeneration itself causes decreased graft compliance, and all the partial regenerating grafts have such risks as portal stealing during regeneration (*28*). Such events are difficult to be forecasted, and because PV stealing with insufficient graft perfusion causes secondary graft injuries, we believe that major portosystemic shunts should be obstructed during transplantation.

Our principle in managing PV hemodynamics in LDLT is represented by simplification and normalization. By obstructing the abnormal portosystemic shunts, all the mesenteric PV flow runs into the LDLT graft without stealing, although PV pressure increases. We obstruct major (defined as ≥10 mm in size on preoperative MDCT) shunts after reperfusion. Thereafter, splenectomy is performed if PV pressure after shunt ligation is 20 mm Hg or greater for PV decompression. Although both procedures seem opposite, they are common in treating abnormal PV hemodynamics caused by end-stage liver diseases. The combination of both procedures simplify and normalize PV hemodynamics and is in contrast to preserved major portosystemic shunts without splenectomy resulting in keeping hyperdynamic PV flow with stealing.

In conclusion, it is an appropriate option to obstruct the major portosystemic shunt vessels to ensure adequate graft inflow in LDLT.

MATERIALS AND METHODS

Patients

Between May 1997 and June 2012, 381 adult-to-adult LDLTs were performed at Kyushu University Hospital, under the approval from the Ethics and Indications Committee of Kyushu University. Cases of acute liver failure (n=56) and LDLT using dual grafts (n=1) were excluded from the present analyses. Thus, 324 adult-to-adult LDLTs for chronic hepatic disorders were included in the current analyses. A total of 130 patients had major spontaneous portosystemic shunts (diameter, ≥10 mm on computed tomography) before LDLT, and 194 patients did not. The mean (SD) follow-up time was 4.8 (3.6) years.

Graft Selection

Grafts were selected as previously described (*30*). Left-lobe grafts were used as the primary graft type if the desired GV/SLV ratio was 35% or greater. Right-lobe grafts were used if the simulated GV/SLV ratio of the left-lobe graft was less than 35% and the donor's remnant liver volume was 35% or greater. Posterior segment grafts were used if GV/SLV ratio of the posterior segment graft was 35% or greater with isolated branching of the posterior PV from the main PV and if both left and right-lobe grafts were not available.

Transplant Procedures

Donor parenchymal transection was performed using the Cavitron Ultrasonic Surgical Aspirator (Valleylab Inc., Boulder, CO) with the hanging maneuver (*31*). After donor hepatectomy, the graft was perfused, weighed, and stored in University of Wisconsin solution (Viaspan; DuPont Inc., Wilmington, DE).

After recipient hepatectomy, the grafts were transplanted in a piggyback fashion. The orifice of the recipient's hepatic vein was enlarged with an incision

on the vena cava for the venous anastomosis to provide sufficient outflow. After venous anastomoses, the PV was reconstructed and reperfused. Subsequent arterial reconstruction was performed under a microscope. If indicated, splenectomy was performed as previously described (*31*). Biliary reconstruction was performed by duct-to-duct biliary anastomosis whenever possible.

Ligation or Division of the Major Shunt Vessels

Since 2000, we have ligated all of the identified major (≥10 mm) portosystemic shunt vessels during LDLT, whenever indicated. The presence of such major portosystemic shunts was diagnosed using MDCT after operation. The shunts are controlled and left open during the anhepatic phase to minimize portal venous congestion and are ligated after reperfusion.

To control splenorenal or gastrorenal shunts, intraoperative sonography was used to identify the left renal vein in the retroperitoneum near the left side of the inferior mesenteric vein. The transverse mesocolon was retracted in a cephalad direction to provide an adequate surgical field. The retroperitoneum was opened, and the left renal vein was identified. By following the left renal vein, a dilated splenorenal shunt was identified on the cranial side and was then controlled as appropriate.

For gastroesophageal shunts, the dilated coronary vein was carefully dissected from the retroperitoneum and controlled, followed by its ligation, before May 2011. However, because this is a technically difficult procedure, caused by the tortuously dilated coronary veins with minor collateral vessels, we have since applied endostapling devices to the base of the left gastric ligament, including the left gastric artery, engorged coronary vein, and collateral vessels, followed by en bloc division using endostapling devices (Echelon Flex Endopath TM Staplers 60-2.5; Ethicon Endo-Surgery Inc., Cincinnati, OH) and mass suturing with continuous 3-0 Prolene sutures with an SH needle (Ethicon Inc., Somerville, NJ) (*23*).

Mesocaval shunts were identified in the retroperitoneum on a case-by-case basis. We routinely ligate the major inflow into the mesocaval shunts and the major outflow into the vena cava.

Establishment of PV Inflow

The presence of major shunt vessels might indicate PV thrombosis or atrophy. Eversion or corkscrew procedures were performed for PV thrombectomy (*32*). Renoportal anastomosis was indicated for complete PV thrombosis with a fragile or atrophic PV vein wall with numerous splenorenal shunts. The left renal vein was controlled after mobilization of the duodenum. End-to-end PV reconstruction was performed using an IJ vein graft with continuous 6-0 polydiaxanone sutures.

For an atrophied PV or complete PV thrombosis with a fragile PV wall, without splenorenal shunts, PV reconstruction was performed using IJ jump grafts, which were connected to the mesenteric-splenic junction or the mesenteric vein. The IJ graft was then tunneled behind the pancreas neck to connect to the PV.

Splenectomy

The indications for splenectomy during LDLT include hypersplenism, PV pressure of 20 mm Hg or greater, and patients with hepatitis C treated with interferon after LDLT. We have introduced tieless splenectomy (*19*) using a vessel-sealing system (LigaSure Atlas; Valleylab Inc., Boulder, CO) and endostapling devices (Echelon Staplers 60-2.5; Ethicon Endo-Surgery Inc.).

Measurement of Portal Hemodynamic Properties

PV pressure was continuously monitored during surgery using a cannula (Medicut LCV-UK catheter 14 GTM; Nippon Sherwood Inc., Tokyo, Japan) placed in the superior mesenteric vein through a terminal jejunal vein. Intraoperative PV flow (L/min) was measured in the recipients using an ultrasonic transit time flow meter (Transonic System, Ithaca, NY) after establishing hepatic artery flow and reperfusion.

Posttransplantation Medical Care

The basic immunosuppression protocol consisted of tacrolimus or cyclosporine with mycophenolate mofetil and steroids. The target tacrolimus level was 10 to 14 ng/mL at 1 month after LDLT and was decreased to 7 to 10 ng/mL during the next few months. The target cyclosporine level was 150 to 250 ng/mL at 1 month after LDLT and was decreased to 100 to 150 ng/mL during the next few months.

Primary graft dysfunction was defined as graft insufficiency with possible early graft loss, without technical, anatomic, immunologic, or hepatitis-related issues. Primary graft dysfunction was detected as delayed hyperbilirubinemia, with a total bilirubin of 20 mg/dL or greater, usually occurring 7 days after surgery and persisting for 7 or more consecutive days. It was treated by plasma exchange (*29*).

Statistical Analysis

All analyses were conducted in a retrospective manner. Values are expressed as the mean (SD). Variables were analyzed using chi-square tests for categorical values or the Mann-Whitney test for continuous variables. Cumulative survival was determined using the Kaplan-Meier method with log-rank tests. $P<0.05$ was considered statistically significant.

ACKNOWLEDGMENTS

The authors thank Takako Shishino, Junko Eguchi, and Hideyuki Konishi for their excellent technical assistance.

REFERENCES

1. Collini FJ, Brener B. Portal hypertension. *Surg Gynecol Obstet* 1990; 170: 177.
2. Rössle M, Siegerstetter V, Huber M, et al. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art. *Liver* 1998; 18: 73.
3. Cosenza CA, Hoffman AL, Friedman ML, et al. Transjugular intrahepatic portosystemic shunt: efficacy for the treatment of portal hypertension and impact on liver transplantation. *Am Surg* 1996; 62: 835.
4. Narahara Y, Kanazawa H, Kawamata H, et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. *Hepatol Res* 2001; 21: 189.
5. Tomikawa M, Hashizume M, Okita K, et al. Endoscopic injection sclerotherapy in the management of 2105 patients with esophageal varices. *Surgery* 2002; 131: S171.
6. Yanaga K, Tzakis AG, Shimada M, et al. Reversal of hypersplenism following orthotopic liver transplantation. *Ann Surg* 1989; 210: 180.
7. Hadengue A, Lebrec D, Moreau R, et al. Persistence of systemic and splanchnic hyperkinetic circulation in liver transplant patients. *Hepatology* 1993; 17: 175.
8. Piscaglia F, Zironi G, Gaiani S, et al. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. *Hepatology* 1999; 30: 58.
9. Jiang SM, Zhang QS, Zhou GW, et al. Differences in portal hemodynamics between whole liver transplantation and living donor liver transplantation. *Liver Transpl* 2010; 16: 1236.
10. Jang YJ, Kim KW, Jeong WK, et al. Influence of preoperative portal hypertension and graft size on portal blood flow velocity in recipient after living donor liver transplantation with right-lobe graft. *AJR Am J Roentgenol* 2010; 194: W165.
11. Sugimoto H, Kato K, Hirota M, et al. Serial measurement of Doppler hepatic hemodynamic parameters for the diagnosis of acute rejection after live donor liver transplantation. *Liver Transpl* 2009; 15: 1119.
12. Nakanishi S, Shiraki K, Yamamoto K, et al. Early graft hemodynamics in living related liver transplantation evaluated by Doppler ultrasonography. *Int J Mol Med* 2004; 14: 265.
13. Kita Y, Harihara Y, Sano K, et al. Reversible hepatofugal portal flow after liver transplantation using a small-for-size graft from a living donor. *Transpl Int* 2001; 14: 217.
14. Sekido H, Matsuo K, Takeda K, et al. Severe fatty change of the graft liver caused by a portosystemic shunt of mesenteric varices. *Transpl Int* 2002; 15: 259.
15. Moon DB, Lee SG, Ahn C, et al. Application of intraoperative cineportogram to detect spontaneous portosystemic collaterals missed by intraoperative Doppler exam in adult living donor liver transplantation. *Liver Transpl* 2007; 13: 1279.
16. Troisi R, Ricciardi S, Smeets P, et al. Effects of hemi-portocaval shunts for inflow modulation on the outcome of small-for-size grafts in living donor liver transplantation. *Am J Transplant* 2005; 5: 1397.
17. Yamada T, Tanaka K, Uryuhara K, et al. Selective hemi-portocaval shunt based on portal vein pressure for small-for-size graft in adult living donor liver transplantation. *Am J Transplant* 2008; 8: 847.

18. Shimada M, Ijichi H, Yonemura Y, et al. The impact of splenectomy or splenic artery ligation on the outcome of a living donor adult liver transplantation using a left lobe graft. *Hepatogastroenterology* 2004; 51: 625.
19. Ikegami T, Toshima T, Takeishi K, et al. Bloodless splenectomy during liver transplantation for terminal liver diseases with portal hypertension. *J Am Coll Surg* 2009; 208: e1.
20. Ikegami T, Soejima Y, Taketomi A, et al. Living donor liver transplantation with extra-small graft: inflow modulation using splenectomy and temporary portocaval shunt. *Hepatogastroenterology* 2008; 55: 670.
21. Yabe S, Egawa H, Inomata Y, et al. Auxiliary partial orthotopic liver transplantation from living donors: significance of portal blood flow. *Transplantation* 1998; 66: 484.
22. Ikegami T, Shiotani S, Ninomiya M, et al. Auxiliary partial orthotopic liver transplantation from living donors. *Surgery* 2002; 131: S205.
23. Ikegami T, Shirabe K, Yoshizumi T, et al. En bloc stapling division of the gastroesophageal vessels controlling portal hemodynamic status in living donor liver transplantation. *J Am Coll Surg* 2012; 214: e53.
24. Lee SG, Moon DB, Ahn CS, et al. Ligation of left renal vein for large spontaneous splenorenal shunt to prevent portal flow steal in adult living donor liver transplantation. *Transpl Int* 2007; 20: 45.
25. Mizuno S, Murata Y, Kuriyama N, et al. Living donor liver transplantation for the patients with portal vein thrombosis: use of an interpositional venous graft passed posteriorly to the pancreatic parenchyma without using jump graft. *Transplant Proc* 2012; 44: 356.
26. Marubashi S, Dono K, Nagano H, et al. Living-donor liver transplantation with renoportal anastomosis for patients with large spontaneous splenorenal shunts. *Transplantation* 2005; 80: 1671.
27. Yoshiya S, Shirabe K, Kimura K, et al. The causes, risk factors, and outcomes of early relaparotomy after living-donor liver transplantation. *Transplantation* 2012; 94: 947.
28. Ikegami T, Shimada M, Imura S, et al. Current concept of small-for-size grafts in living donor liver transplantation. *Surg Today* 2008; 38: 971.
29. Ikegami T, Shirabe K, Yoshizumi T, et al. Primary graft dysfunction after living donor liver transplantation is characterized by delayed functional hyperbilirubinemia. *Am J Transplant* 2012; 12: 1886.
30. Soejima Y, Shirabe K, Taketomi A, et al. Left lobe living donor liver transplantation in adults. *Am J Transplant* 2012; 12: 1877.
31. Taketomi A, Morita K, Toshima T, et al. Living donor hepatectomies with procedures to prevent biliary complications. *J Am Coll Surg* 2010; 211: 456.
32. Molmenti EP, Roodhouse TW, Molmenti H, et al. Thrombendvenectomy for organized portal vein thrombosis at the time of liver transplantation. *Ann Surg* 2002; 235: 292.

Hepatology Research

Hepatology Research 2013; 43: 1313–1320 doi: 10.1111/hepr.12091

Original Article

Risk factors for recurrence after curative resection of hepatitis C-related hepatocellular carcinoma in patients without postoperative interferon therapy

Yo-ichi Yamashita,[1,2] Ken Shirabe,[1] Takeo Toshima,[1] Eiji Tsuijita,[2] Kazuki Takeishi,[2] Norifumi Harimoto,[1] Toru Ikegami,[1] Tomoharu Yoshizumi,[1] Tetsuo Ikeda,[1] Yuji Soejima[1] and Yoshihiko Maehara[1]

[1]*Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, and* [2]*Department of Surgery, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Hiroshima, Japan*

Aim: Hepatitis C (HC)-related hepatocellular carcinoma (HCC; HC-HCC) is highly recurrent.

Methods: From 1995–2007, 183 curative hepatic resections for primary solitary HC-HCC without postoperative interferon therapy were included in this study. The patients were divided into three groups: (i) 2 cm or less ($n = 56$); (ii) more than 2 cm to less than 5 cm ($n = 79$); and (iii) 5 cm or more ($n = 48$). Independent risk factors for HC-HCC recurrence for each group were determined.

Results: Independent risk factors for recurrence were aspartate aminotransferase or alanine aminotransferase (AST/ALT) of 80 IU/L or more (hazard ratio [HR], 2.1; $P = 0.02$) in patients with HCC of 2 cm or less, des-γ-carboxy prothrombin of 100 mAU/mL or more (HR, 2.5; $P = 0.02$) and AST/ALT of 80 IU/L or more (HR, 2.1; $P = 0.04$) in patients with HCC of more than 2 cm to less than 5 cm, and the presence of macroscopic portal vein tumor thrombus (HR, 2.8; $P = 0.02$) and AST/ALT of 80 IU/L or more (HR, 2.1; $P = 0.04$) in patients with HCC of 5 cm or more. All 13 late recurrences of 1 year or more after hepatic resection (27.1%) in patients with HCC of 5 cm or more were accompanied by AST/ALT of 80 IU/L or more.

Conclusion: AST/ALT of 80 IU/L or more is an independent risk factor for the recurrence of primary solitary HC-HCC after curative resection irrespective of the primary HC-HCC size.

Key words: hepatitis C virus, hepatocellular carcinoma, risk factors, tumor recurrence

INTRODUCTION

HEPATOCELLULAR CARCINOMA (HCC) is one of the most common malignancies worldwide, with at least 1 million new cases annually.[1] The cause of HCC is infection with a hepatitis virus such as hepatitis B virus (HBV) or hepatitis C virus (HCV).[2] The mechanism of carcinogenesis by HCV is still unknown. HCV is an RNA virus that does not integrate into the DNA of hepatocytes. Theoretically, HCV, unlike HBV, does not have a direct oncogenic mechanism.[3] Chronic inflammation, liver cell necrosis and regeneration, and extensive fibrosis are important in the development of hepatitis C-related HCC (HC-HCC).[3]

Despite improvements in imaging and surgical procedures, outcomes after hepatic resection for HCC are still unsatisfactory because of the high rate of recurrence.[4] Recurrence is considered to be caused by two factors, metastasis of cancer cells and multicentric occurrence, in patients after curative resection of HCC. We extensively examined the recurrence pattern of HC-HCC and found that recurrence-free survival after hepatic resection for HC-HCC is deeply related to hepatitis activity.[5–8] This activity, represented by high serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) levels, was thought to be related to multicentric occurrence,[9,10] but metastasis of cancer cells was related to characteristics of advanced

Correspondence: Dr Yo-ichi Yamashita, Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Email: yamashi@surg2.med.kyushu-u.ac.jp

Received 21 November 2012; revision 6 February 2013; accepted 7 February 2013.

tumor stage such as large tumor size or portal vein tumor thrombus.[11,12] Several randomized controlled trial studies confirmed the effectiveness of postoperative interferon therapy for HC-HCC,[13,14] but the target of this therapy is thought to be a multicentric occurrence, not metastasis. To establish a postoperative treatment strategy for HC-HCC, the risk factors for the recurrence from the aspects of metastasis or multicentric occurrence need to be evaluated.

In the present study, we analyzed 183 consecutive patients who had undergone curative hepatic resections for primary solitary HC-HCC from 1995–2007, and who had received more than 5 years' follow up without postoperative interferon therapy at a single institution. We determined the independent risk factors for recurrence by dividing the primary HC-HCC size into three size groups: (i) HCC of 2 cm or less; (ii) HCC of more than 2 cm to less than 5 cm; and (iii) HCC of 5 cm or more.

METHODS

Patients

A TOTAL OF 219 anti-HCV antibody positive patients who had undergone curative hepatic resections for primary solitary HC-HCC at the Department of Surgery, Hiroshima Red Cross and Atomic Bomb Survivors Hospital, between January 1995 and December 2007 were included in this study. Thirty-six patients were excluded for the following reasons: five patients had tested negative for serum HCV RNA, one patient had died during hospital stay, and 30 patients had received postoperative interferon therapy. Hence, there were 183 evaluative patients in our series. Curative resection was defined as a complete tumor resection without tumor exposure, as confirmed by pathological examination. Patients were divided into three groups according to primary HC-HCC size: (i) HCC of 2 cm or less ($n = 56$); (ii) HCC of more than 2 cm to less than 5 cm ($n = 79$); and (iii) HCC of 5 cm or more ($n = 48$). The medical records of all patients were followed up through March 2012. The median follow-up periods in our series were 7.6, 6.8 and 5.4 years, respectively.

Surgical techniques and follow-up methods

Details of the surgical techniques and patient selection criteria have been reported previously.[15,16] The resection volume was decided based on the indocyanine green retention rate at 15 min (ICG-R15). Patients with an ICG-R15 of 35% or more were selected for limited resection.[16] In almost all hepatic resections, Pringle's maneuver, consisting of clamping the portal triad for 15 min and then releasing the clamp for 5-min intervals was applied; alternatively, hemivascular occlusion[17,18] was performed. The CUSA system (Valleylab, Boulder, CO., USA) was used to transect the liver parenchyma.

After discharge, all patients were examined for recurrence by ultrasonography and tumor markers such as α-fetoprotein and des-γ-carboxy prothrombin (DCP) each month, and by dynamic computed tomography every 3 or 4 months.[19] No patients in this series received adjuvant chemotherapy. We treated recurrent HCC by repeat hepatectomy,[20] ablation therapy or lipiodolization[21] according to a previously described strategy.[22]

Statistical analysis

The disease-free survival (DFS) curves were generated by the Kaplan–Meier method and compared by the log-rank test. To evaluate the independent risk factors for recurrence of HC-HCC after curative hepatic resection in each group, we performed multivariate analysis with the Cox proportional hazard model, using a variable-selection method involving the backward-elimination procedure. The cut-off for elimination was set at $P < 0.15$. The following 16 clinical, surgical and tumor-related variables were analyzed:[16] age (≥65 years vs younger); the mean serum total bilirubin level after hepatic resection (≥1.0 mg/dL vs less); preoperative ICG-R15 (≥20% vs less); the mean serum albumin level after hepatic resection (≥3.5 g/dL vs less); the mean serum AST/ALT (either AST or ALT) levels assessed by the data obtained each month for 1 year after hepatic resection (≥80 IU/L vs less); histological cirrhosis (present vs absent); macroscopic portal vein tumor thrombus (VP; present vs absent); preoperative α-fetoprotein (≥100 ng/mL vs less); preoperative DCP (≥100 IU/L vs less); pathological cancer spread including portal vein invasion (vp) and intrahepatic metastasis (im) (present vs absent); tumor cell differentiation (well or moderate vs poor); surgical time (≥300 min vs less); surgical blood loss (≥1000 mL vs less); operative procedure (anatomical resection vs limited resection); history of intraoperative blood cell transfusion (yes vs no); and surgical margin (≥5 mm vs smaller). Categorical variables were compared using either the χ^2-test or Fisher's exact test, as appropriate. All analyses were performed with Statview 5.0 software (Abacus Concepts, Berkeley, CA, USA). *P*-values of less than 0.05 were considered to indicate statistical significance.

RESULTS

Rates of vp and im

TABLE 1 SHOWS the rates of vp and im in each group. In patients with HCC of 2 cm or less, the vp and im rates were 5.4% and 1.8%, respectively. In patients with HCC of more than 2 cm to less than 5 cm, the vp rate increased significantly to 29.1% ($P = 0.03$). In patients with HCC of 5 cm or more, the vp and im rates increased markedly to 81.3% ($P < 0.01$) and 58.3% ($P < 0.01$), respectively.

Independent risk factors for recurrence of HC-HCC in each group

Table 2 summarizes the results of univariate analysis according to the risk factors for recurrence of HC-HCC in patients with HCC of 2 cm or less. Table 3 shows that the independent risk factor for recurrence was found to be AST/ALT of 80 IU/L or more (hazard ratio [HR], 2.1; $P = 0.02$). The DFS curves of the two groups divided by AST/ALT or ICG-R15 values are illustrated in Figure 1. The DFS was significantly worse in patients with AST/ALT of 80 IU/L or more ($P = 0.03$). In this group, the 1- and 3-year DFS in patients with AST/ALT of 80 IU/L or more versus those with AST/ALT of less than 80 IU/L were 80% versus 95%, and 49% versus 72%, respectively.

Table 4 summarizes the results of univariate analysis according to the risk factors for recurrence of HC-HCC in patients with HCC of more than 2 cm to less than 5 cm. As Table 5 shows, the independent risk factors for recurrence were DCP of 100 mAU/mL or more (HR, 2.5; $P = 0.02$) and AST/ALT of 80 IU/L or more (HR, 2.1; $P = 0.04$). The DFS curves of the two groups divided by DCP or AST/ALT values are illustrated in Figure 2. The DFS was significantly worse in patients with DCP of 100 mAU/mL or more ($P = 0.02$). In this group, the 1- and 3-year DFS in patients with AST/ALT of 80 IU/L or more versus with AST/ALT of less than 80 IU/L were 82% versus 84% and 53% versus 80%, respectively.

Table 1 Rates of vp and im according to the primary HC-HCC size

Tumor diameter	vp	im
HCC ≤2 cm ($n = 56$)	3 (5.4%)	(1.8%)
HCC >2 cm to <5 cm ($n = 79$)	23 (29.1%)*	3 (3.8%)
HCC ≥5 cm ($n = 48$)	39 (81.3%)**	28 (58.3%)**

*$P = 0.03$, **$P < 0.01$.
HC, hepatitis C; HCC, hepatocellular carcinoma; im, intrahepatic metastasis; vp, portal vein invasion.

Table 2 Univariate analysis for risk factors of recurrence: HCC ≤2 cm

Variables	5-year disease free survival	*P*-value
Background characteristics		
Age ≥65 years	Yes, 24%; no, 30%	0.87
T-bil ≥1.0 mg/dL	Yes, 23%; no, 32%	0.44
ICG-R15 ≥20%	Yes, 17%; no, 39%	0.09
Alb <3.5 g/dL	Yes, 31%; no, 33%	0.82
AST/ALT ≥80 IU/L	Yes, 20%; no, 50%	0.03
Surgical outcomes		
Surgical time ≥300 min	Yes, 21%; no, 40%	0.22
Surgical blood loss ≥1000 mL	Yes, 29%; no, 32%	0.97
Transfusion (+)	Yes, 28%; no, 49%	0.19
Limited resection	Yes, 13%; no, 46%	0.05
Surgical margin <5 mm	Yes, 17%; no, 38%	0.21
Tumor-related factors		
VP (+)	Yes, 0%; no, 39%	0.89
Cancer spread (+)	Yes, 18%; no, 23%	0.88
Poorly differentiated	Yes, 40%; no, 50%	0.25
AFP ≥100 ng/mL	Yes, 0%; no, 36%	0.09
DCP ≥100 mAU/L	Yes, 35%; no, 38%	0.37
Histological cirrhosis (+)	Yes, 12%; no, 44%	0.17

Alb, albumin; AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; cancer spread, pathological cancer spread including portal vein invasion and intrahepatic metastasis; DCP, des-γ-carboxy prothrombin; HCC, hepatocellular carcinoma; ICG-R15, indocyanine green retention rate at 15 min; T-bil, total bilirubin; VP, macroscopic portal vein tumor thrombus.

Table 6 summarizes the results of univariate analysis according to the risk factors for recurrence of HC-HCC in patients with HCC of 5 cm or more. As Table 7 shows, the independent risk factors for recurrence were VP+ (HR, 2.8; $P = 0.02$) and AST/ALT of 80 IU/L or more (HR, 2.1; $P = 0.04$). The DFS curves of the two groups divided by the VP or AST/ALT value are illustrated in

Table 3 Independent risk factors for recurrence: HCC ≤2 cm

Variables	Hazard ratio	95% CI	*P*-value
AST/ALT ≥80 IU/L	2,1	1.28–3.84	0.02
ICG-R15 ≥20%	1.6	0.82–3.68	0.15
AFP ≥100 ng/mL	1.5	0.18–1.33	0.16
Limited resection	1.4	0.67–3.17	0.19

AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; HCC, hepatocellular carcinoma; ICG-R15, indocyanine green retention rate at 15 min.



Figure 1 In patients with hepatocellular carcinoma (HCC) ≤2 cm, the disease-free survival (DFS) curves of the two groups divided by aspartate aminotransferase (AST)/alanine aminotransferase (ALT) (≥80 IU/L or <80 IU/L) or indocyanine green retention rate at 15 min (ICG-R15) (≥20% or <20%) values are illustrated. The DFS was significantly worse in patients with AST/ALT ≥80 IU/L ($P = 0.03$). ----, AST/ALT <80 IU/L ($n = 22$); ——, AST/ALT ≥80 IU/L ($n = 34$); ----, ICG-R15 <20% ($n = 35$); ——, ICG-R15 ≥20% ($n = 21$).

Table 4 Univariate analysis for risk factors of recurrence: HCC of more than 2 cm to less than 5 cm

Variables	5-year disease free survival	*P*-value
Background characteristics		
Age ≥65 years	Yes, 28%; no, 39%	0.11
T-bil ≥1.0 mg/dL	Yes, 39%; no, 39%	0.95
ICG-R15 ≥20%	Yes, 17%; no, 43%	0.03
Alb <3.5 g/dL	Yes, 23%; no, 36%	0.16
AST/ALT ≥80 IU/L	Yes, 27%; no, 51%	0.06
Surgical outcomes		
Surgical time ≥300 min	Yes, 31%; no, 52%	0.32
Surgical blood loss ≥1000 mL	Yes, 37%; no, 39%	0.59
Transfusion (+)	Yes, 23%; no, 48%	0.47
Limited resection	Yes, 20%; no, 41%	0.01
Surgical margin <5 mm	Yes, 29%; no, 32%	0.86
Tumor-related factors		
VP (+)	Yes, 27%; no, 31%	0.62
Cancer spread (+)	Yes, 29%; no, 32%	0.55
Poorly differentiated	Yes, 24%; no, 35%	0.35
AFP ≥100 ng/mL	Yes, 25%; no, 36%	0.18
DCP ≥100 mAU/L	Yes, 27%; no, 42%	0.04
Histological cirrhosis (+)	Yes, 21%; no, 44%	0.02

AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; cancer spread, pathological cancer spread including portal vein invasion and intrahepatic metastasis; DCP, des-γ-carboxy prothrombin; HCC, hepatocellular carcinoma; ICG-R15, the indocyanine green dye retention rate at 15 minutes; T-bil, total bilirubin; VP, macroscopic portal vein tumor thrombus.

Figure 3. The DFS was significantly worse in patients with VP+ ($P = 0.04$). In this group, the 1- and 3-year DFS in patients with AST/ALT of 80 IU/L or more versus with AST/ALT of less than 80 IU/L were 47% versus 72% and 32% versus 56%, respectively.

Recurrence patterns according to the primary HC-HCC size

Table 8 summarizes the pattern of recurrence, such as solitary liver recurrence, multiple liver recurrence or distant recurrence after curative resection of HC-HCC in each group. In patients with HCC of 2 cm or less, 39 patients (69.6%) had tumor recurrence. The rate of solitary liver recurrence (62.5%) was significantly higher in this group ($P < 0.01$). Among the patients with HCC of

Table 5 Independent risk factors for recurrence: HCC more than 2 cm to less than 5 cm

Variables	Hazard ratio	95% CI	*P*-value
DCP ≥100 mAU/L	2.5	1.10–4.00	0.02
AST/ALT ≥80 IU/L	2.1	1.02–6.33	0.04
Age ≥65 years	1.9	1.00–3.70	0.06
Limited resection	1.4	0.67–3.17	0.12
ICG-R15 ≥20%	1.0	0.43–2.12	0.91
Histological cirrhosis (+)	1.1	0.40–2.12	0.92

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; HCC, hepatocellular carcinoma; ICG-R15, the indocyanine green dye retention rate at 15 minutes.



Figure 2 In patients with hepatocellular carcinoma (HCC) of more than 2 cm to less than 5 cm, the disease-free survival (DFS) curves of the two groups divided by des-γ-carboxy prothrombin (DCP) (≥100 or <100 mAU/mL) or aspartate aminotransferase (AST)/alanine aminotransferase (ALT) (≥80 or <80 IU/L) values are illustrated. The DFS was significantly worse in patients with DCP ≥100 mAU/mL ($P = 0.02$). ----, DCP <100 mAU/mL ($n = 43$); —, DCP ≥100 mAU/mL ($n = 36$); ----, AST/ALT <80 IU/L ($n = 26$); —, AST/ALT ≥80 IU/L ($n = 53$).

Table 6 Univariate analysis for risk factors of recurrence: HCC ≥5 cm

Variables	5-year disease free survival	*P*-value
Background characteristics		
Age ≥65 years	Yes, 7%; no, 22%	0.23
T-bil ≥1.0 mg/dL	Yes, 0%; no, 13%	0.39
ICG-R15 ≥20%	Yes, 0%; no, 21%	0.02
Alb <3.5 g/dL	Yes, 0%; no, 12%	0.63
AST/ALT ≥80 IU/L	Yes, 12%; no, 25%	0.09
Surgical outcomes		
Surgical time ≥300 min	Yes, 0%; no, 24%	0.25
Surgical blood loss ≥1000 mL	Yes, 0%; no, 17%	0.56
Transfusion (+)	Yes, 0%; no, 18%	0.89
Limited resection (+)	Yes, 5%; no, 22%	0.14
Surgical margin <5 mm	Yes, 8%; no, 23%	0.38
Tumor-related factors		
VP (+)	Yes, 0%; no, 20%	0.04
Cancer spread (+)	Yes, 0%; no, 18%	0.93
Poorly differentiated	Yes, 11%; no, 17%	0.28
AFP ≥100 ng/mL	Yes, 7%; no, 22%	0.81
DCP ≥100 mAU/L	Yes, 0%; no, 14%	0.85
Histological cirrhosis (+)	Yes, 0%; no, 19%	0.18

AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; cancer spread, pathological cancer spread including portal vein invasion and intrahepatic metastasis; DCP, des-γ-carboxy prothrombin; HCC, hepatocellular carcinoma; ICG-R15, the indocyanine green dye retention rate at 15 minutes; T-bil, total bilirubin; VP, macroscopic portal vein tumor thrombus.

more than 2 cm to less than 5 cm, 54 (68.4%) had tumor recurrence. The rates of solitary liver recurrence, multiple liver recurrence and distant recurrence were 53.2%, 11.4% and 3.8%, respectively. In patients with HCC of 5 cm or more, 36 patients (75.0%) had tumor recurrence. The rates of multiple liver recurrence (37.5%) and distant recurrence (20.8%) were significantly higher in this group ($P = 0.02$ and $P = 0.04$, respectively).

Duration of recurrence according to the primary HC-HCC size

Table 9 summarizes the durations of recurrence, such as within 1 year (<1 year; early recurrence) or after 1 year (≥1 year; late recurrence) in each group. In patients with HCC of 2 cm or less, 32 patients (57.0%) had late recurrence, a significantly higher rate ($P = 0.04$). In patients with HCC of more than 2 cm to less than 5 cm, 13

Table 7 Independent risk factors for recurrence: HCC ≥5 cm

Variables	Hazard ratio	95% CI	*P*-value
VP (+)	2.8	1.52–7.41	0.02
AST/ALT ≥80 IU/L	2.1	1.04–5.34	0.04
ICG-R15 ≥20%	1.6	0.21–1.74	0.28
Limited resection	1.3	0.47–1.57	0.53

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; HCC, hepatocellular carcinoma; ICG-R15, the indocyanine green dye retention rate at 15 minutes; VP, macroscopic portal vein tumor thrombus.



Figure 3 In patients with hepatocellular carcinoma (HCC) ≥5 cm, the disease-free survival (DFS) curves of the two groups divided by portal vein tumor thrombus (VP; – or +) or aspartate aminotransferase (AST)/alanine aminotransferase (ALT) (≥80 or <80 IU/L) are illustrated. The DFS was significantly worse in patients with VP+ ($P = 0.04$). ----, VP– ($n = 34$); ——, VP+ ($n = 14$); ----, AST/ALT <80 IU/L ($n = 14$); ——, AST/ALT ≥80 IU/L ($n = 34$).

patients (16.5%) had early recurrence and 41 patients (51.9%) had late recurrence. In patients with HCC of 5 cm or more, 23 patients (47.9%) had early recurrence, a significantly higher rate ($P = 0.01$). In addition, all 13 patients (27.1%) with late recurrence had the risk factor of AST/ALT of 80 IU/L or more.

DISCUSSION

TWO FACTORS WERE thought to be the causes of HC-HCC recurrence in patients after curative hepatic resection: 'metastasis of cancer cells and multicentric occurrence'. Early recurrence of HC-HCC would relate mainly to metastasis of cancer cells, whereas recurrence of HC-HCC would relate mainly to multicentric occurrence.[23] A review of the published work suggests that the risk factors for recurrence of HC-HCC can be divided roughly into two groups, tumor-related factors, such as tumor size[11] and portal vein invasion,[12] and remnant liver-related factors, such as hepatitis activity and liver fibrosis.[5–8] Generally speaking, patients with tumor-related risk factors for the recurrence of HC-HCC would face early recurrence, and patients with remnant liver-related risk factors for recurrence of HC-HCC would face late recurrence. Also in our series, early recurrence (<1 year) was common (47.9%) in patients with HCC of 5 cm or more, and late recurrence (≥1 year) was predominant in both patients with HCC of 2 cm or less (57.0%) and patients with HCC of more than 2 cm to less than 5 cm (51.9%).

Previous reports have shown that hepatitis activity is an important factor for the recurrence of HC-HCC. We have shown that the histological hepatitis activity and postoperative levels of transaminase are significant risk factors for HC-HCC recurrence in small HCC.[5–8] To assess hepatitis activity, periodical biopsies of residual liver after hepatic resection would provide accurate information, but this would not be acceptable on ethical grounds. Serum AST/ALT level was thought to relate to remnant liver inflammatory necrosis,[9,10] and in our series, AST/ALT (either AST or ALT) of 80 IU/L or more

Table 8 Recurrence patterns according to the primary HC-HCC size

Tumor diameter	Liver, solitary	Liver, multiple	Distant
HCC ≤2 cm	35*	3	1
(39/56; 69.6%)	(62.5%)	(5.4%)	(1.8%)
>2 cm to <5 cm	42	9	3
(54/79; 68.4%)	(53.2%)	(11.4%)	(3.8%)
HCC ≥5 cm	8	18**	10**
(36/48; 75.0%)	(16.7%)	(37.5%)	(20.8%)

*$P < 0.01$, **$P = 0.02$, ***$P = 0.04$.
HC, hepatitis C; HCC, hepatocellular carcinoma.

Table 9 Durations of recurrence according to the primary HC-HCC size

Tumor diameter	<1 year	≥1 year
HCC ≤2 cm	7	32*
(39/56; 69.6%)	(12.5%)	(57.0%)
>2 cm to <5 cm	13	41
(54/79; 68.4%)	(16.5%)	(51.9%)
HCC ≥5 cm	23**	13
(36/48; 75.0%)	(47.9%)	(27.1%)

*$P < 0.01$, **$P = 0.01$.
HC, hepatitis C; HCC, hepatocellular carcinoma.

was an independent risk factor for HC-HCC recurrence after curative hepatic resection, irrespective of the primary HC-HCC size. We picked not preoperative but postoperative serum AST/ALT level to assess the effects of postoperative hepatitis activity in our series.

We have reported the improvement of long-term outcomes in HC-HCC in the modern era.[24] The effectiveness of postoperative interferon therapy for HC-HCC was confirmed by several randomized controlled trial studies,[13,14] but the target of this therapy is thought to be multicentric occurrence rather than metastasis of cancer cells. In our series, patients with HCC of 5 cm or more had significantly high rates of multiple liver recurrence (37.5%) and distant recurrence (20.8%) within 1 year postoperatively.

We reported that a combination of two factors such as HCC of 5 cm or more and DCP of 300 mAU/mL or more was useful in the selection of candidates for living donor liver transplantation for HCC.[25] These would be the most important tumor-related factors in the recurrence of HCC because the remnant liver disappeared in living donor liver transplantation. In our series, DCP of 100 mAU/mL or more is an independent risk factor for the recurrence of HC-HCC in patients with HCC of more than 2 cm to less than 5 cm, and VP+ is an independent risk factor for the recurrence of HC-HCC in patients with HCC of 5 cm or more.

Another possible factor in the high recurrence rate of active hepatitis is the enhancement of metastasis by upregulated adhesion molecules on the sinusoidal lining cells of the liver.[26,27] Our own results suggest, however, that remnant liver inflammation represented by AST/ALT of 80 IU/L or more should be a risk factor for multicentric recurrence in the late period. According to our own series in long-term follow up, even in patients with HCC of 5 cm or more, AST/ALT of 80 IU/L or more was a risk factor for HC-HCC recurrence in the late period. However, in patients with AST/ALT of 80 IU/L or more, Figure 1 (HCC, ≤2 cm) demonstrates the high rate of recurrence of HC-HCC within 2 years and the same low rate of recurrence of HC-HCC after 5 years. Of the nine patients with HCC of 2 cm or less who had a recurrence of HC-HCC within 2 years, seven (78%) had pathological cancer spreads or poor differentiation.[28] The low rate of recurrence of HC-HCC after 5 years in patients with HCC of 2 cm or less might have been due to the relatively short follow-up period (median, 7.6 years).

In conclusion, AST/ALT of 80 IU/L or more is an independent risk factor for recurrence of primary solitary HC-HCC after curative resection, irrespective of the primary HC-HCC size. AST/ALT of 80 IU/L or more is considered a risk factor for multicentric occurrence in the late period. A good target of postoperative interferon therapy would be patients with primary HC-HCC of less than 5 cm or patients with HCC of 5 cm or more 1 year or more after hepatic resection.

REFERENCES

1 Lau WY. Management of hepatocellular carcinoma. *J R Coll Surg Edinb* 2002; **47**: 389–99.
2 Tsai JF, Jeng JE, Ho MS *et al.* Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. *Br J Cancer* 1997; **76**: 968–74.
3 Sherlock S. Viruses and hepatocellular carcinoma. *Gut* 1994; **35**: 828–32.
4 Liver Cancer Study Group of Japan. Primary liver cancer in Japan: primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. *Ann Surg* 1990; **211**: 277–87.
5 Adachi E, Maeda T, Matsumata T *et al.* Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. *Gastroenterology* 1995; **108**: 768–75.
6 Shirabe K, Takenaka K, Taketomi A *et al.* Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. *Cancer* 1996; **77**: 1050–5.
7 Shirabe K, Wakiyama S, Gion T *et al.* Clinicopathological risk factors linked to recurrence pattern after curative hepatic resection for hepatocellular carcinoma – results of 152 resected cases. *Hepatogastroenterology* 2007; **54**: 2084–7.
8 Shirabe K, Shimada M, Kajiyama K *et al.* Clinicopathologic features of patients with hepatocellular carcinoma surviving >10 years after hepatic resection. *Cancer* 1998; **83**: 2312–6.
9 Tarao K, Takemiya S, Tamai S *et al.* Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. *Cancer* 1997; **79**: 688–94.
10 Tarao K, Rino Y, Takemiya S *et al.* Close association between high serum ALT and more rapid recurrence of hepatocellular carcinoma in hepatectomized patients with HCV-associated liver cirrhosis and hepatocellular carcinoma. *Intervirology* 2000; **43**: 20–6.
11 Yeh CN, Chen MF, Lee WC, Jeng LB. Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis. *J Surg Oncol* 2002; **81**: 195–202.
12 Kubo S, Hirohashi K, Tanaka H *et al.* Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. *World J Surg* 2000; **24**: 1559–65.
13 Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term

outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. *Br J Surg* 2002; **89**: 418–22.
14 Ikeda K, Arase Y, Saitoh S *et al.* Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. *Hepatology* 2000; **32**: 228–32.
15 Shimada M, Takenaka K, Fujiwara Y *et al.* Risk factors linked to postoperative morbidity in patients with hepatocellular carcinoma. *Br J Surg* 1998; **85**: 195–8.
16 Yamashita Y, Taketomi A, Itoh S *et al.* Long-term favorable results of limited hepatic resections for patients with hepatocellular carcinoma: 20 years of experience. *J Am Coll Surg* 2007; **205**: 19–26.
17 Makuuchi M, Mori T, Gunvén P, Yamazaki S, Hasegawa H. Safety of hemihepatic vascular occlusion during resection of the liver. *Surg Gynecol Obstet* 1987; **164**: 155–8.
18 Lanois B. The intrahepatic Glissonian approach to liver resection. In: Blumgart LH, Fong Y, eds. *Surgery of the Liver and Biliary Tract*, 3rd edn. Vol. 2. London: WB Saunders, 2000; 1698–703.
19 Takenaka K, Kawahara N, Yamamoto K *et al.* Results of 280 liver resections for hepatocellular carcinoma. *Arch Surg* 1996; **131**: 71–6.
20 Shimada M, Takenaka K, Taguchi K *et al.* Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma. *Ann Surg* 1998; **227**: 80–5.
21 Kanematsu T, Furuta T, Takenaka K *et al.* A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. *Hepatology* 1989; **10**: 98–102.
22 Shimada M, Takenaka K, Gion T *et al.* Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. *Gastroenterology* 1996; **111**: 720–6.
23 Portolani N, Coniglio A, Ghidoni S *et al.* Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. *Ann Surg* 2006; **243**: 229–35.
24 Shirabe K, Takeishi K, Taketomi A, Uchiyama H, Kayashima H, Maehara Y. Improvement of long-term outcomes in hepatitis C virus antibody-positive patients with hepatocellular carcinoma after hepatectomy in the modern era. *World J Surg* 2011; **35**: 1072–84.
25 Taketomi A, Sanefuji K, Soejima Y *et al.* Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. *Transplantation* 2009; **87**: 531–7.
26 Volpes R, Van Den Oord JJ, Desmet VJ. Vascular adhesion molecules in acute and chronic liver inflammation. *Hepatology* 1992; **15**: 269–75.
27 Volpes R, van den Oord JJ, Desmet VJ. Immunohistochemical study of adhesion molecules in liver inflammation. *Hepatology* 1990; **12**: 59–65.
28 Yamashita Y, Tsuijita E, Takeishi K *et al.* Predictors for microinvasion of small hepatocellular carcinoma ≤ 2 cm. *Ann Surg Oncol* 2012; **19**: 2027–34.

Sweden, and the Juvenile Diabetes Research Foundation. O.K. is in part supported by the National Institutes of Health (grant 2U01AI065192-06).
The authors declare no conflicts of interest.
Address correspondence to: Andrew S. Friberg, Ph.D., Division of Clinical Immunology, Department of Immunology, Genetics and Pathology, Uppsala University, Rudbeck Laboratory, C11, Dag Hammarskjölds väg 20, SE-75185 Uppsala, Sweden.
E-mail: andrew.friberg@igp.uu.se
A.S.F., O.K., and M.H. participated in the research design, performed the experiments and data analysis, and wrote the article.
Received 19 October 2012. Revision requested 12 November 2012.
Accepted 17 December 2012.

ISSN: 0041-1337/13/9506-e36
DOI: 10.1097/TP.0b013e318283a859

REFERENCES

1. Antonioli B, Fermo I, Cainarca S, et al. Characterization of collagenase blend enzymes for human islet transplantation. *Transplantation* 2007; 84: 1568.
2. Barnett MJ, Zhai X, LeGatt DF, et al. Quantitative assessment of collagenase blends for human islet isolation. *Transplantation* 2005; 80: 723.
3. Balamurugan AN, Breite AG, Anazawa T, et al. Successful human islet isolation and transplantation indicating the importance of class 1 collagenase and collagen degradation activity assay. *Transplantation* 2010; 89: 954.
4. Brandhorst H, Asif S, Andersson K, et al. The effect of truncated collagenase class I isomers on human islet isolation outcome. *Transplantation* 2010; 90: 334.
5. Brandhorst H, Brendel MD, Eckhard M, et al. Influence of neutral protease activity on human islet isolation outcome. *Transplant Proc* 2005; 37: 241.
6. Kin T, O'Gorman D, Senior P, et al. Experience of islet isolation without neutral protease supplementation. *Islets* 2010; 2: 278.
7. Kin T, Zhai X, O'Gorman D, et al. Detrimental effect of excessive collagenase class II on human islet isolation outcome. *Transpl Int* 2008; 21: 1059.
8. Kin T, Zhai X, Murdoch TB, et al. Enhancing the success of human islet isolation through optimization and characterization of pancreas dissociation enzyme. *Am J Transplant* 2007; 7: 1233.
9. Wolters GH, Vos-Scheperkeuter GH, van Deijnen JH, et al. An analysis of the role of collagenase and protease in the enzymatic dissociation of the rat pancreas for islet isolation. *Diabetologia* 1992; 35: 735.
10. Brandhorst H, Friberg A, Andersson HH, et al. The importance of tryptic-like activity in purified enzyme blends for efficient islet isolation. *Transplantation* 2009; 87: 370.
11. Balamurugan AN, Loganathan G, Bellin MD, et al. A new enzyme mixture to increase the yield and transplant rate of autologous and allogeneic human islet products. *Transplantation* 2012; 93: 693.
12. Cross SE, Hughes SJ, Partridge CJ, et al. Collagenase penetrates human pancreatic islets following standard intraductal administration. *Transplantation* 2008; 86: 907.
13. Balamurugan AN, He J, Guo F, et al. Harmful delayed effects of exogenous isolation enzymes on isolated human islets: relevance to clinical transplantation. *Am J Transplant* 2005; 5: 2671.
14. Van Wart HE, Steinbrink DR. A continuous spectrophotometric assay for *Clostridium histolyticum* collagenase. *Anal Biochem* 1981; 113: 356.
15. Goto M, Eich TM, Felldin M, et al. Refinement of the automated method for human islet isolation and presentation of a closed system for in vitro islet culture. *Transplantation* 2004; 78: 1367.
16. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976; 72: 248.
17. Stoscheck CM. Quantitation of protein. *Methods Enzymol* 1990; 182: 50.

Impact of Conversion From Pegylated Interferon-α2b to Interferon-α2a for Treating Recurrent Hepatitis C After Liver Transplantation

The clinical outcomes of conversion from pegylated (peg) interferon (IFN)-α2b to peg-IFN-α2a therapy in combination with ribavirin for recurrent hepatitis C after liver transplantation (LT) have not been reported (*1–3*).

Living-donor liver transplantation (LDLT) was performed in 156 patients for hepatitis C at Kyushu University. Of these, 103 received peg-IFN-α2b and ribavirin and 22 patients underwent conversion from peg-IFN-α2b to peg-IFN-α2b. Indications for conversion included (a) no response (NR; n=14) to peg-IFN-α2b, (b) relapse after viral response (VR; n=5) following completing peg-IFN-α2b therapy, and (c) to prevent relapse (n=3) for VR during peg-IFN-α2b and ribavirin therapy. Splenectomy was performed in 47 (95.9%) recipients to prevent pancytopenia associated with antiviral therapy (*4*). The immunosuppression was induced with triple therapy of tacrolimus or cyclosporine with mycophenolate mofetil and steroids (*5*).

Peg-IFN-α2b with ribavirin (Pegintron with Rebetol; Merck & Co., Whitehouse Station, NJ) was used as the primary treatment for recurrent hepatitis C after LDLT. Peg-IFN-α2b was started at the dose of 0.5–1.0 μg/kg per week with 200–400 mg per day of ribavirin. The doses were escalated in a stepwise manner up to 1.5 μg/kg per week and 800 mg per day. Peg-IFN-α2a with ribavirin (Pegasys with Copegus; Chugai Pharmaceutical, Chuo-ku, Tokyo, Japan) was primarily used for patients with NR or relapse during treatment with peg-IFN-α2b with ribavirin. Peg-IFN-α2a was started at the dose of 90–120 μg per week with 200–400 mg per day of ribavirin. The doses were escalated in a stepwise manner up to 180 μg per week and 800 mg per day. The serum hepatitis C virus (HCV)-RNA level was determined by a real-time HCV assay (Accu-Gene HCV; Abbott Molecular, Des Plaines, IL) and IL28B genotyping was performed using TaqMan GTXpress Master Mix (Life Technologies, Tokyo, Japan). Peg-IFN-induced immune-mediated graft dysfunction (peg-IGD) was defined as the Levitsky et al. (*6*) did. Values are expressed as mean±standard deviation. Variables were analyzed using χ^2 tests for categorical values or the Mann–Whitney test for continuous variables. Values of $P<0.05$ were considered statistically significant.

The characteristics of the patients who underwent conversion from peg-IFN-α2b to peg-IFN-α2a antiviral treatment are described in Table 1. The outcomes of conversion from peg-IFN-α2b to peg-IFN-α2a antiviral treatment are summarized in Figure 1. Among the 14 patients with NR following peg-IFN-α2b with ribavirin therapy, 6 patients achieved VR and 3 had sustained VR (SVR) after conversion. Among the five patients with viral relapse following peg-IFN-α2b–based therapy, four patients achieved VR after conversion. Among the three patients with conversion during

TABLE 1. Patient characteristics

Variables	Values
Recipient age, yr	51.4±8.6 (54.5)
Recipient gender, male	15 (68.2)
Donor age, yr	35.7±11.3 (34.5)
Donor gender, male	16 (72.7)
Left lobe graft	13 (59.7)
GV/SLV (%)	41.4±6.4 (40.4)
Splenectomy	17 (77.3)
Tacrolimus	12 (54.5)
Mycophenolate mofetil	20 (54.5)
Steroid free	5 (22.7)
HCV-RNA titer at LDLT, log IU/mL	5.5±0.6 (5.7)
IFN before LDLT	9 (40.9)
HCV genotype 1b, 2a, and 2b	16 (72.7), 5 (22.7), and 1 (4.6)
Donor rs8099917 genotype, T/T	7 (31.8)
Recipient rs8099917 genotype, T/T	8 (36.4)
Time from LDLT to peg-IFN-a2b, mo	14.3±18.2 (8.1)
Peg-IFN-a2b dose, mg/kg/wk	1.1±0.3 (1.0)
Ribavirin dose peg-IFN-a2b, mg/kg/d	6.1±2.9 (6.2)
Duration of peg-IFN-a2b treatment, mo	12.1±14.2 (10.7)
HCV-RNA titer at conversion, log IU/mL	4.1±2.6 (4.9)
Peg-IFN-a2a dose, mg/kg/wk	2.1±0.8 (1.9)
Ribavirin dose with peg-IFN-a2a, mg/kg/d	3.5±4.3 (2.1)
Duration of peg-IFN-a2a treatment, mo	14.2±10.1 (9.8)
VR with peg-IFN-a2b	8 (36.4)

GV, graft volume; HCV, hepatitis C virus; IFN, interferon; LDLT, living-donor liver transplantation; peg, pegylated; SLV, standard liver volume; VR, viral response.

VR by peg-IFN-α2b–based therapy, two patients achieved SVR. However, all three patients with conversion during VR by peg-IFN-α2b–based therapy had peg-IGD, including de novo autoimmune hepatitis (n=2) and chronic rejection (n=1), resulting in graft loss in two patients.

The viral status after peg-IFN conversion is summarized in Table 2. Among patients with NR, relapse after VR, HCV-RNA seropositivity, and VR following peg-IFN-α2b, the rates of VR after converting to peg-IFN-α2a were 42.8%, 100.0%, 57.9%, and 100.0%, respectively. The rates of SVR were 21.4%, 80.0%, 36.8%, and 40.9%, respectively.

Univariate analysis was performed to identify factors associated with VR after conversion from peg-IFN-α2a to peg-IFN-α2b. In this analysis, only history of VR during peg-IFN-α2a with ribavirin treatment (57.1% vs. 0.0%; P=0.02) was significantly associated with VR after conversion (Table 3). By contrast, low HCV-RNA titer at conversion (1.8±1.9 vs. 5.3±2.0 log IU/mL; P<0.01) and history of VR during peg-IFN-α2a with ribavirin treatment (66.7% vs. 14.3%; P=0.03) were significantly associated with SVR after conversion (Table 4).

The major structural difference between peg-IFN-α2b and peg-IFN-α2a is the conjugated polyethylene glycol (*7–10*). Peg-IFN-α2b (12 kDa) has a single-branched polyethylene glycol, whereas peg-IFN-α2a (40 kDa) has bulky multiple branched conjugates. Consequently, peg-IFN-α2a has a smaller distribution volume (10 vs. 40 L), longer absorption half-life (50 vs. 4.6 hr), and longer elimination half-life (80 vs. 40 hr). Moreover, it was reported that the serum concentration of peg-IFN-α2a was 20 mg/mL at 7 days after injection compared with almost zero for peg-IFN-α2b (*8*).

As a posttransplantation primary antiviral agent for recurrent hepatitis C, peg-IFN-α2a was used in very limited series, and peg-IFN-α2b has become the most widely used and studied regimen for use after LT (*11–13*). Among them, Dinges et al. (*14*) only reported the actual rate of SVR (47%) following peg-IFN-α2a with ribavirin for 19 patients after LT, whereas dose



FIGURE 1. Twenty-two patients who received peg-IFN-α2b with ribavirin were converted to peg-IFN-α2a with or without ribavirin. *AIH (n=1); **AIH (n=1); ***AIH (n=1) and CR (n=1). AIH, autoimmune hepatitis; CR, chronic rejection; IFN, interferon; NR, no response; peg, pegylated; SVR, sustained viral response; VR, viral response.

TABLE 2. Viral status after conversion from peg-IFN-α2b to peg-IFN-α2a antiviral therapy

Response to peg-IFN-α2b	VR for peg-IFN-α2a (%)	SVR for peg-IFN-α2a (%)
NR	6/14 (42.8)	3/14 (21.4)
Relapse after VR	5/5 (100.0)	4/5 (80.0)
Positive HCV-RNA	11/19 (57.9)	7/19 (36.8)
VR	3/3 (100.0)	2/3 (67.7)
Total	14/22 (63.6)	9/22 (40.9)

HCV, hepatitis C virus; IFN, interferon; NR, no response: peg, pegylated; SVR, sustained viral response; VR, viral response.

modification was necessary in 26% of patients. Although their study was small and nonrandomized, the rate of SVR was superior to that achieved by peg-IFN-α2b with ribavirin (~30%) (*15*).

Restarting peg-IFN-α2a with ribavirin in nontransplantation settings after a poor response to previous IFN therapy has been reported in a few studies (*16–18*). Jensen et al. (*16*) conducted a randomized trial in which treatment was restarted in 950 patients who did not respond to prior peg-IFN-α2b with ribavirin therapy. In that study, the rate of SVR after 72 weeks of peg-IFN-α2a with ribavirin treatment was 16%. Herrine et al. (*17*) randomized 124 patients with poor response to peg-IFN-α2b with ribavirin therapy. In that study, 37% of patients had SVR after conversion to peg-IFN-α2a with ribavirin. Therefore, we think that the 21.4% of SVR rate after conversion from peg-IFN-α2b to IFN-α2a is fairly acceptable.

However, the main adverse outcome of conversion to peg-IFN-α2a is peg-IGD, a concept recently proposed by Levitsky et al. (*6*). It was reported that IFN could lead to IGD, which may include acute rejection, chronic rejection, and autoimmune hepatitis as well as graft loss (*15, 19, 20*). They reported that

TABLE 3. Predictors for VR after conversion from peg-IFN-α2b to peg-IFN-α2a

	VR		
Variables	No (n=6)	Yes (n=14)	*P*
Recipient age, yr	58.8±5.1	51.4±8.6	0.85
Recipient gender, male	3 (50.0)	11 (78.6)	0.20
Donor age, yr	32.5±11.1	34.5±9.5	0.68
Donor gender, male	3 (50.0)	11 (78.6)	0.20
Left lobe graft	3 (50.0)	8 (57.1)	0.77
GV/SLV, %	41.7±4.7	41.1±7.6	0.84
Splenectomy	4 (66.7)	11 (78.6)	0.57
Tacrolimus	4 (66.7)	6 (42.6)	0.33
Mycophenolate mofetil	6 (100.0)	12 (85.7)	0.33
Steroid free	2 (33.3)	3 (21.4)	0.57
HCV-RNA titer at LDLT, log IU/mL	5.7±0.2	5.6±0.6	0.67
IFN before LDLT	2 (33.3)	6 (42.9)	0.69
HCV genotype 1b, 2a, and 2b	6 (100.0)	9 (64.3)	0.09
Donor rs8099917 genotype, T/T	3 (50.0)	11 (78.6)	0.20
Recipient rs8099917 genotype, T/T	3 (50.0)	9 (64.3)	0.55
Time from LDLT to peg-IFN-a2b, mo	12.1±18.5	16.0±19.6	0.67
Peg-IFN-a2b dose, mg/kg/wk	1.1±0.3	1.0±0.3	0.35
Ribavirin dose, with peg-IFN-a2b, mg/kg/d	6.6±3.8	5.6±2.8	0.77
Duration of peg-IFN-a2b treatment, mo	20.8±24.8	8.9±5.6	0.52
HCV-RNA titer at conversion, log IU/mL	4.7±2.8	3.5±2.6	0.34
Peg-IFN-a2a dose, mg/kg/wk	2.2±0.8	1.9±0.8	0.51
Ribavirin dose, with peg-IFN-a2a, mg/kg/d	3.3±5.4	2.8±3.3	0.81
Duration of peg-IFN-a2a treatment, mo	26.7±16.2	12.9±10.5	0.06
VR with peg-IFN-a2b	0 (0.0)	8 (57.1)	0.02

GV, graft volume; HCV, hepatitis C virus; IFN, interferon; LDLT, living-donor liver transplantation; peg, pegylated; SLV, standard liver volume; VR, viral response.

TABLE 4. Predictors for SVR after conversion from peg-IFN-α2b to peg-IFN-α2a

Variables	SVR		P
	No (n=7)	Yes (n=9)	
Recipient age, yr	55.9±6.1	51.7±9.1	0.21
Recipient gender, male	4 (57.1)	7 (77.8)	0.38
Donor age, yr	33.7±12.1	39.0±9.5	0.30
Donor gender, male	3 (42.8)	8 (88.9)	0.06
Left lobe graft	4 (57.1)	5 (55.6)	0.95
GV/SLV (%)	42.6±5.5	39.2±7.7	0.24
Splenectomy	5 (71.4)	6 (66.7)	0.84
Tacrolimus	5 (71.4)	4 (44.4)	0.28
Mycophenolate mofetil	7 (100.0)	6 (66.7)	0.69
Steroid free	3 (42.8)	2 (22.2)	0.38
HCV-RNA titer at LDLT, log IU/mL	5.6±0.5	5.4±0.7	0.57
IFN before LDLT	2 (28.5)	4 (44.4)	0.51
HCV genotype 1b, 2a, 2b	7 (100.0)	6 (66.7)	0.09
Donor rs8099917 genotype, T/T	4 (57.1)	8 (88.9)	0.14
Recipient rs8099917 genotype, T/T	4 (57.1)	6 (66.7)	0.69
Time from LDLT to peg-IFN-a2b, mo	10.3±12.5	21.6±24.8	0.17
Peg-IFN-a2b dose, mg/kg/wk	1.1±0.3	1.0±0.3	0.35
Ribavirin dose, with peg-IFN-a2b, mg/kg/d	6.0±3.7	5.7±3.1	0.84
Duration of peg-IFN-a2b treatment, mo	12.7±17.6	11.1±5.4	0.78
HCV-RNA titer at conversion, log IU/mL	5.3±2.0	1.8±1.9	<0.01
Peg-IFN-a2a dose, mg/kg/wk	2.0±0.8	1.5±0.5	0.13
Ribavirin dose, with peg-IFN-a2a, mg/kg/d	3.2±5.0	2.6±3.2	0.79
Duration of peg-IFN-a2a treatment, mo	26.7±16.2	16.3±12.1	0.23
VR with peg-IFN-a2b	1 (14.3)	6 (66.7)	0.03

GV, graft volume; HCV, hepatitis C virus; IFN, interferon; LDLT, living-donor liver transplantation; peg, pegylated; SLV, standard liver volume; SVR, sustained viral response; VR, viral response.

7.2% of patients treated with peg-IFN develop peg-IGD over 10 years, with a significantly higher mortality rate. Additionally, the use of peg-IFN-α2a (odds ratio=4.7) was a significant risk factor for this event (*6*). In the current series, peg-IGD occurred in all three patients who converted from peg-IFN-α2b to peg-IFN-α2a, with graft loss in two patients.

In conclusion, conversion to peg-IFN-α2a–based antiviral therapy for recurrent hepatitis C after LT is a safe option, with increased VR and SVR rate, only for patients with NR or relapse on previous peg-IFN-α2b therapy.

Toru Ikegami[1]
Ken Shirabe[1]
Tomoharu Yoshizumi[1]
Norihiro Furusyo[2]
Kazuhiro Kotoh[3]
Masaki Kato[3]
Shinji Shimoda[4]
Yuji Soejima[1]
Takashi Motomura[1]
Takasuke Fukuhara[1]
Yoshihiko Maehara[1]

[1] Department of Surgery and Science
Graduate School of Medical Sciences
Kyushu University
Fukuoka, Japan
[2] Department of General Internal Medicine
Graduate School of Medical Sciences
Kyushu University
Fukuoka, Japan
[3] Department of Medicine
and Bioregulatory Science
Graduate School of Medical Sciences
Kyushu University
Fukuoka, Japan
[4] Department of Medicine
and Biosystemic Science
Graduate School of Medical Sciences
Kyushu University
Fukuoka, Japan

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan.
The authors declare no conflicts of interest.
Address correspondence to: Toru Ikegami, M.D., Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
E-mail: tikesurg@ysurg2.med.kyushu-u.ac.jp
T.I. participated in the study conception and design and drafting of the article. K.S. participated in the critical revision of the article. T.Y. participated in the statistical analysis. N.F., T.M., and T.F. participated in the DNA analysis. K.K. participated in the study conception and design. M.K. and S.S. participated in the collection of clinical data. Y.S. participated in the pathologic examination. Y.M. participated in the final approval of the article.
Received 14 November 2012. Revision requested 10 December 2012.
Accepted 17 December 2012.

ISSN: 0041-1337/13/9506-e38
DOI: 10.1097/TP.0b013e318283a82e

REFERENCES

1. Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha-2a is associated with higher sustained virological response than Peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. *Hepatology* 2010; 51: 1176.
2. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and